Teva Pharmaceutical Industries
TEVA
39.18
+0.05
+0.13%
Teva Pharmaceutical Industries
US · TEVA
#471 by market cap
Listed 1970
39.18
+0.05
+0.13%
Live - 5344 symbols - heartbeat 229s ago
· 2026-10-08 07:05
Pre-market
38.61
-1.45%
After-hours
39.18
0.00%
Overnight
38.80
-0.97%
- Market cap
- 45.70B
- P/E (TTM)i
- 65.30
- P/Bi
- 5.89
- EPSi
- 1.21
- Div yieldi
- 0.00%
- 52W posi
- 93%
Reader sentiment
Are you bullish or bearish on TEVA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 4 analysts
Buy
Avg price target
45.00 +14.9%
Price target rangecurrent 39.18
Low42.00
Avg45.00
High50.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-24 | J.P. Morgan | -- | BUY | -- |
| 2026-09-23 | BofA Securities | -- | BUY | 43.00 |
| 2026-09-23 | Oppenheimer | -- | BUY | 50.00 |
| 2026-08-11 | Barclays | -- | BUY | 42.00 |
| 2026-06-22 | Scotiabank | -- | BUY | 40.00 |
| 2026-06-18 | Jefferies | -- | BUY | 40.00 |
| 2026-06-15 | Scotiabank | -- | BUY | 40.00 |
| 2026-06-15 | J.P. Morgan | -- | BUY | -- |
| 2026-06-10 | Piper Sandler | -- | BUY | 42.00 |
| 2026-06-01 | Piper Sandler | -- | BUY | 42.00 |
| 2026-05-27 | Jefferies | -- | BUY | 40.00 |
| 2026-05-06 | Barclays | -- | BUY | 40.00 |
| 2026-04-30 | UBS | -- | BUY | 42.00 |
| 2026-04-30 | Piper Sandler | -- | BUY | 42.00 |
| 2026-04-30 | BofA Securities | -- | BUY | 40.00 |
| 2026-04-30 | Truist Financial | -- | BUY | 45.00 |
| 2026-04-30 | Scotiabank | -- | BUY | 40.00 |
| 2026-04-30 | Goldman Sachs | -- | BUY | 50.00 |
| 2026-04-30 | J.P. Morgan | -- | BUY | 40.00 |
| 2026-04-29 | BofA Securities | -- | BUY | 40.00 |
| 2026-04-29 | Truist Financial | -- | BUY | 45.00 |
| 2026-04-23 | Piper Sandler | -- | BUY | 41.00 |
| 2026-04-15 | Piper Sandler | -- | BUY | 41.00 |
| 2026-04-09 | BofA Securities | -- | BUY | -- |
| 2026-03-27 | Barclays | -- | BUY | 38.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C
Momentum strategy signal
Buy
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-29 | -- | ±6.19% | +9.60% (beat) |
| 2026/Q1 | 2026-04-29 | -- | ±12.22% | +11.89% (in line) |
| 2025/Q4 | 2026-01-28 | -- | ±6.43% | +2.09% (in line) |
| 2025/Q3 | 2025-11-05 | -- | ±6.14% | +20.23% (beat) |
| 2025/Q2 | 2025-07-30 | -- | ±8.15% | +1.75% (in line) |
| 2025/Q1 | 2025-05-07 | -- | ±9.79% | +9.18% (in line) |
| 2024/Q4 | 2025-01-29 | -- | ±7.94% | -13.89% (beat) |
| 2024/Q3 | 2024-11-06 | -- | ±7.99% | -7.14% (in line) |
| 2024/Q2 | 2024-07-31 | -- | ±10.41% | +6.22% (in line) |
| 2024/Q1 | 2024-05-08 | -- | ±7.44% | +12.83% (beat) |
| 2023/Q4 | 2024-01-31 | -- | ±9.30% | +3.15% (in line) |
| 2023/Q3 | 2023-11-08 | -- | ±9.55% | +1.22% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:05:36 · For reference only, not investment advice and not tailored to your situation.